Dyne Therapeutics Future Growth
Future criteria checks 2/6
Dyne Therapeutics is forecast to grow earnings and revenue by 13.5% and 66.8% per annum respectively. EPS is expected to grow by 20.8% per annum. Return on equity is forecast to be -44.6% in 3 years.
Key information
13.5%
Earnings growth rate
20.8%
EPS growth rate
Biotechs earnings growth | 30.1% |
Revenue growth rate | 66.8% |
Future return on equity | -44.6% |
Analyst coverage | Good |
Last updated | 15 Aug 2024 |
Recent future growth updates
Recent updates
Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth
Aug 14Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials
May 21We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
May 04Dyne: H2 2024 Muscle Disease Data Could Boost Value
Mar 05We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
Dec 05Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
Aug 09We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
Mar 26We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully
Dec 10Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?
Aug 26Dyne wins regulatory nod to start trial for myotonic dystrophy candidate
Jul 12Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251
Jul 05Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
May 05We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely
Jan 12We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth
Sep 29Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down
Jun 02Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
May 12Dyne Therapeutics EPS beats by $0.10
May 06Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?
Jan 27Dyne Therapeutics posts encouraging data from its pre-clinical myotonic dystrophy trial
Jan 11Beneficiary Dyne Therapeutics rises on competitor Sarepta's miss in DMD trial
Jan 08Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 11 | -335 | -314 | -298 | 6 |
12/31/2025 | 1 | -315 | -290 | -260 | 9 |
12/31/2024 | N/A | -273 | -291 | -232 | 9 |
6/30/2024 | N/A | -258 | -220 | -219 | N/A |
3/31/2024 | N/A | -257 | -220 | -220 | N/A |
12/31/2023 | N/A | -236 | -189 | -188 | N/A |
9/30/2023 | N/A | -208 | -184 | -182 | N/A |
6/30/2023 | N/A | -189 | -176 | -175 | N/A |
3/31/2023 | N/A | -177 | -152 | -150 | N/A |
12/31/2022 | N/A | -168 | -157 | -154 | N/A |
9/30/2022 | N/A | -181 | -157 | -153 | N/A |
6/30/2022 | N/A | -182 | -141 | -137 | N/A |
3/31/2022 | N/A | -160 | -157 | -152 | N/A |
12/31/2021 | N/A | -149 | -123 | -120 | N/A |
9/30/2021 | N/A | -126 | -114 | -112 | N/A |
6/30/2021 | N/A | -97 | -98 | -96 | N/A |
3/31/2021 | N/A | -77 | -59 | -58 | N/A |
12/31/2020 | N/A | -59 | -48 | -47 | N/A |
9/30/2020 | N/A | -36 | -32 | -30 | N/A |
6/30/2020 | N/A | -28 | -23 | -22 | N/A |
3/31/2020 | N/A | -21 | -18 | -17 | N/A |
12/31/2019 | N/A | -15 | -13 | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DYN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DYN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DYN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DYN's revenue (66.8% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: DYN's revenue (66.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DYN is forecast to be unprofitable in 3 years.